{"protocolSection": {"identificationModule": {"nctId": "NCT01334125", "orgStudyIdInfo": {"id": "13938"}, "organization": {"fullName": "University of Massachusetts, Worcester", "class": "OTHER"}, "briefTitle": "Adjunctive Metformin Therapy in Double Diabetes", "officialTitle": "Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen", "acronym": "AMTIDD"}, "statusModule": {"statusVerifiedDate": "2016-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-02"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-21", "studyFirstSubmitQcDate": "2011-04-11", "studyFirstPostDateStruct": {"date": "2011-04-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-01-27", "resultsFirstSubmitQcDate": "2016-03-03", "resultsFirstPostDateStruct": {"date": "2016-03-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-03-03", "lastUpdatePostDateStruct": {"date": "2016-03-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Benjamin U. Nwosu", "investigatorTitle": "Study Principle Investigator", "investigatorAffiliation": "University of Massachusetts, Worcester"}, "leadSponsor": {"name": "University of Massachusetts, Worcester", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The significance of this project is to investigate the effects of adjunctive metformin therapy in children and adolescents with double diabetes. Double diabetes describes a clinical state where an individual possesses features of both type 1 and type 2 diabetes. There is a paucity of data on the role of adjunctive metformin therapy in children and adolescents with double diabetes. To help fill this knowledge gap, the investigators propose a randomized, double-blind, placebo-controlled trial of metformin in double diabetes. Specifically, the investigators will evaluate changes in hemoglobin A1c and anthropometry in patients with a diagnosis of type 1 diabetes who also have features of type 2 diabetes or metabolic syndrome as well as patients with type 2 diabetes who possess diabetes-associated autoantibodies. This will help determine the safety profile, and efficacy of adjunctive metformin therapy in these subjects.", "detailedDescription": "In this 12-month clinical trial, a 3-month run-in period will precede the interventional phase of the study. All patients will be placed on treat-to-target insulin regimen alone during the run-in phase. At the end of the 3-month run-in period, all participants will continue on treat-to-target insulin regimen, and will then be randomized to either of the 2 arms of the study: an experimental arm, consisting of treat-to-target insulin regimen plus metformin, and a control arm consisting of treat-to-target insulin regimen plus placebo. Both the physicians and patients will be blinded to the oral agents being administered to patients."}, "conditionsModule": {"conditions": ["Diabetes Mellitus"], "keywords": ["Double Diabetes", "Type 1 diabetes", "Type 2 diabetes", "Obesity", "Acanthosis nigricans", "Diabetes associated autoantibodies"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Metformin", "type": "EXPERIMENTAL", "description": "Metformin 1000 mg once daily by mouth for 9 months", "interventionNames": ["Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "2 capsules once daily by mouth for 9 months", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months", "armGroupLabels": ["Metformin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Placebo", "description": "2 capsules once daily by mouth for 9 months", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Adjusted Hemoglobin A1c Over Time", "description": "Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "timeFrame": "Baseline, 3mo, 6mo, and 9 months"}], "secondaryOutcomes": [{"measure": "Baseline Adjusted Changes in Lipid Profile Over Time", "description": "Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "timeFrame": "Baseline, 3mo, 6mo, and 9 months"}, {"measure": "Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time", "description": "Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "timeFrame": "Baseline, 3mo, 6 mo, and 9 months"}, {"measure": "Number of Participants With Minor, Major, and Nocturnal Hypoglycemia", "description": "Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of \\<60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of \u226460 mg/dL between 11PM and 6AM).", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nA. General inclusion criteria\n\n1. Ten to 20 years of age.\n2. Pubertal (Tanner stages 2-5, by examination).\n3. Hemoglobin A1c level of \\> 8.0% in the 6 months prior to enrollment.\n4. All subjects must have access to a computer.\n\nB. Specific inclusion criteria: \\[Subjects could have either #1, or #2\\].\n\n1. Subjects with clinical and biochemical features of T2DM of \\> 6mo duration who also have positive T1DM antibodies\n\n   * Clinical features: acanthosis nigricans, BMI \\>85%\n   * Biochemical: evidence of insulin resistance at diagnosis\n   * fasting insulin \\>27 uIU/mL(normal range 6-27) at a fasting blood glucose of \u2265 126 mg/dL, or\n   * fasting c-peptide level of \\> 7.1 ng/mL (normal range 0.9 - 7.1), or\n   * Homeostasis model of insulin resistance of \\>3.16\n2. Patients with T1DM of \\> one yr duration with BMI \\>85%\n\n   * Presentation with ketoacidosis at diagnosis\n   * C-peptide \\<0.9 ng/mL (normal range 0.9 - 7.1),or (insulin \\< 6 uIU/mL) (NR 6-27) at diagnosis (when blood glucose is \u2265 126 mg/dL)\n   * Can be antibody positive or negative\n   * Increased insulin requirement (\\>2 Units/kg/day)\n\nExclusion Criteria:\n\n1. Subjects on weight altering medications, such as orlistat.\n2. Subjects with eating disorder\n3. Subjects on medications other than insulin and or metformin that may affect blood glucose level.\n4. Subjects with abnormal hepatic function tests.\n5. Subjects with nephropathy, defined in this case as an overnight albumin excretion rate of \\>200 mcg/min using a first morning urine sample collection.\n6. Subjects with recurrent diabetes ketoacidosis (more than 2 episodes in the past 12 months), or recurrent severe hypoglycemia (more than 2 episodes of hypoglycemia with altered level of consciousness, requiring assistance to treat in the past year).\n7. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.\n8. Known or suspected allergy to metformin.\n9. The receipt of any investigational drug within 6 months prior to this trial.\n10. Active malignant neoplasms.\n11. No access to a computer.\n12. Subjects currently taking metformin for clinical purposes are not eligible to be enrolled in this study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "10 Years", "maximumAge": "20 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Benjamin U Nwosu, MD", "affiliation": "University of Massachusetts, Worcester", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UmassMemorial Medical Center", "city": "Worcester", "state": "Massachusetts", "zip": "01655", "country": "United States", "geoPoint": {"lat": 42.26259, "lon": -71.80229}}]}, "referencesModule": {"references": [{"pmid": "26367281", "type": "RESULT", "citation": "Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, Barton BA, Lee MM. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes. PLoS One. 2015 Sep 14;10(9):e0137525. doi: 10.1371/journal.pone.0137525. eCollection 2015."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Following enrollment, all subjects entered a run-in phase of 3-month duration during which participants were placed on insulin aspart and insulin detemir, and the treat-to-target insulin regimen (TTIR) started.", "recruitmentDetails": "This study was conducted at a tertiary institution. The first patient was recruited on March 3rd 2011, and the last study patient was recruited on August 1, 2013. The study was closed on August 8, 2013.", "groups": [{"id": "FG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "FG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsule once daily by mouth for 9 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "3 subjects move to another city", "numSubjects": "12"}, {"groupId": "FG001", "comment": "3 subjects left for college and moved out of the area", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Subjects who completed the baseline evaluation at the time of randomization were included in the baseline analysis.", "groups": [{"id": "BG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "BG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsules once daily by mouth for 9 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "28"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15", "spread": "2.5"}, {"groupId": "BG001", "value": "14.5", "spread": "3.1"}, {"groupId": "BG002", "value": "14.7", "spread": "2.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "28"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Adjusted Hemoglobin A1c Over Time", "description": "Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, 3mo, 6mo, and 9 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsules once daily by mouth for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.46", "lowerLimit": "8.47", "upperLimit": "10.46"}, {"groupId": "OG001", "value": "9.85", "lowerLimit": "8.82", "upperLimit": "10.88"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analyses were based on the intent-to-treat principle and were performed using SPSS v.22 (IBM Corporation, Armonk, NY).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.903", "pValueComment": "Individual two-way mixed ANOVA models were fitted for each of our outcomes of interest, with treatment type (metformin or placebo) as the fixed effect, and baseline values, age, gender, and BMI as covariates.", "statisticalMethod": "ANOVA", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Baseline Adjusted Changes in Lipid Profile Over Time", "description": "Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "Baseline, 3mo, 6mo, and 9 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsule once daily by mouth for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "lowerLimit": "3.0", "upperLimit": "4.1"}, {"groupId": "OG001", "value": "4", "lowerLimit": "3.3", "upperLimit": "4.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analyses were based on the intent-to-treat principle and were performed using SPSS v.22 (IBM Corporation, Armonk, NY).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.578", "pValueComment": "Individual two-way mixed ANOVA models were fitted for each of our outcomes of interest, with treatment type (metformin or placebo) as the fixed effect, and baseline values, age, gender, and BMI as covariates.", "statisticalMethod": "ANOVA", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Baseline Adjusted Changes in Adiponectin/Leptin Ratio Over Time", "description": "Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "Baseline, 3mo, 6 mo, and 9 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsule once daily by mouth for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "lowerLimit": "0.84", "upperLimit": "3.2"}, {"groupId": "OG001", "value": "1.2", "lowerLimit": "0.11", "upperLimit": "2.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Two way ANOVA comparison of the means of the adiponectin/leptin ratios between the metformin and placebo groups", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.057", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Number of Participants With Minor, Major, and Nocturnal Hypoglycemia", "description": "Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of \\<60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of \u226460 mg/dL between 11PM and 6AM).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months"}, {"id": "OG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsule once daily by mouth for 9 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"title": "Major hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Minor hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Nocturnal hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "p value represents the analysis for minor hypoglycemia", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "1.00", "statisticalMethod": "t-test, 2 sided"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "p value represents the analysis of the nocturnal hypoglycemia", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "1.00", "statisticalMethod": "t-test, 2 sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "12 months", "eventGroups": [{"id": "EG000", "title": "Metformin", "description": "Metformin 1000 mg once daily by mouth for 9 months\n\nMetformin: Metformin 1000 mg once daily by mouth for 9 months", "seriousNumAffected": 4, "seriousNumAtRisk": 15, "otherNumAffected": 1, "otherNumAtRisk": 15}, {"id": "EG001", "title": "Placebo", "description": "1 capsule once daily by mouth for 9 months\n\nPlacebo: 1 capsule once daily by mouth for 9 months", "seriousNumAffected": 1, "seriousNumAtRisk": 13, "otherNumAffected": 3, "otherNumAtRisk": 13}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Endocrine disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Severe hypoglycemia", "organSystem": "Endocrine disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}], "otherEvents": [{"term": "Eye infection", "organSystem": "Eye disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Otitis media", "organSystem": "Ear and labyrinth disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Hidradenitis", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The trial was stopped before reaching enrollment target because most youth were reluctant to commit to this long-term study."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Benjamin U. Nwosu, MD", "organization": "University of Massachusetts Medical School", "email": "Benjamin.Nwosu@umassmemorial.org", "phone": "5083347872"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "relevance": "LOW"}, {"id": "M51", "name": "Acanthosis Nigricans", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "BC17", "name": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M4625", "name": "Autoantibodies", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}